|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...56789101112131415...4041» |
- || Betaseron (IFN-β-1b) / Bayer
Trial primary completion date, Adherence: BETAEVAL: BAY86-5046 (Betaseron), Non Interventional Studies (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=150, Recruiting, Sponsor: Bayer
Trial primary completion date: Sep 2015 --> Mar 2016
- || dimethyl fumarate / Generic mfg.
Trial primary completion date: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - Dec 6, 2015
P2, N=70, Recruiting, Sponsor: Biogen
Trial primary completion date: Sep 2015 --> Mar 2016 Trial primary completion date: Nov 2015 --> Jul 2016
- Enrollment closed, Trial primary completion date: Upper Limbs Intervention in Multiple Sclerosis (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Universidad de Granada
Trial primary completion date: Nov 2015 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Aug 2015
- ||||||| Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Dec 5, 2015
P3, N=201, Completed, Sponsor: Biogen
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Aug 2015 Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal, Trial primary completion date: Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Stirling
Active, not recruiting --> Completed N=12 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2012 --> Nov 2012
- doxycycline / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Doxycycline In Lymphangioleiomyomatosis (LAM) (clinicaltrials.gov) - Dec 5, 2015
P4, N=24, Completed, Sponsor: University of Nottingham
N=12 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2012 --> Nov 2012 Active, not recruiting --> Completed | N=40 --> 24 | Trial primary completion date: Apr 2013 --> Jan 2013
- mexiletine / Generic mfg.
Trial primary completion date: Mexiletine for the Treatment of Muscle Cramps in ALS (clinicaltrials.gov) - Dec 5, 2015
P4, N=30, Recruiting, Sponsor: Bjorn Oskarsson, MD
Active, not recruiting --> Completed | N=40 --> 24 | Trial primary completion date: Apr 2013 --> Jan 2013 Trial primary completion date: Oct 2015 --> Mar 2016
- Enrollment closed: CISAVID: Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome (clinicaltrials.gov) - Dec 5, 2015
P2, N=84, Active, not recruiting, Sponsor: University College Dublin
Trial primary completion date: Oct 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- Trial completion, Adherence: Development of a Motivational Intervention to Improve Treatment Adherence in MS (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=80, Completed, Sponsor: University of Missouri, Kansas City
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| teriflunomide / Generic mfg.
Trial completion, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Dec 5, 2015
P4, N=1001, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Biomarker, Enrollment closed: Neuroretinal Biomarkers in Neurodegenerative Diseases (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: University of Edinburgh
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=40, Completed, Sponsor: University of Missouri, Kansas City
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial primary completion date: Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis? (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Feb 2016
- || vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2015
P2, N=168, Recruiting, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Sep 2015 --> Feb 2016 Trial primary completion date: May 2016 --> Nov 2015
- Enrollment change, Trial withdrawal: Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=0, Withdrawn, Sponsor: Echosense Ltd.
Trial primary completion date: May 2016 --> Nov 2015 N=20 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment change, Trial withdrawal: Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc) (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=0, Withdrawn, Sponsor: Echosense Ltd.
N=20 --> 0 | Not yet recruiting --> Withdrawn N=20 --> 0 | Recruiting --> Withdrawn
- Enrollment change, Trial termination: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=5, Terminated, Sponsor: Echosense Ltd.
N=20 --> 0 | Recruiting --> Withdrawn N=20 --> 5 | Recruiting --> Terminated; Low recruitment rate
- Enrollment change, Trial termination: Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=1, Terminated, Sponsor: Echosense Ltd.
N=20 --> 5 | Recruiting --> Terminated; Low recruitment rate N=20 --> 1 | Not yet recruiting --> Terminated; Low recruitment rate
- fingolimod / Generic mfg.
Enrollment closed, Trial primary completion date: Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=125, Active, not recruiting, Sponsor: University of Southern California
N=20 --> 1 | Not yet recruiting --> Terminated; Low recruitment rate Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- | bortezomib / Generic mfg.
Trial completion: Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 3, 2015
P2, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Completed
- Enrollment change, Trial termination: Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes (clinicaltrials.gov) - Nov 30, 2015
P=N/A, N=56, Terminated, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Completed N=90 --> 56 | Recruiting --> Terminated; Inclusion curve too slow.
- Trial primary completion date: Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Nov 28, 2015
P=N/A, N=1118, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=90 --> 56 | Recruiting --> Terminated; Inclusion curve too slow. Trial primary completion date: Sep 2015 --> Sep 2016
- Trial completion, Enrollment change, Trial primary completion date: ELY-SLA: A New Eye-based Communication Device for ALS Patients (clinicaltrials.gov) - Nov 28, 2015
P=N/A, N=12, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Completed | N=18 --> 12 | Trial primary completion date: Aug 2015 --> Apr 2015
- dalfampridine / Generic mfg.
Trial initiation date, Trial termination, Trial primary completion date: Fampridine Pregnancy Exposure Registry (clinicaltrials.gov) - Nov 25, 2015
P=N/A, N=375, Terminated, Sponsor: Biogen
Recruiting --> Completed | N=18 --> 12 | Trial primary completion date: Aug 2015 --> Apr 2015 Initiation date: Dec 2015 --> Aug 2015 | Recruiting --> Terminated | Trial primary completion date: Oct 2020 --> Dec 2015; Due to low enrollment, registration closed in agreement with the Regulatory Agency
- Biomarker, Trial completion: BIO_ALS-01: Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Nov 25, 2015
P=N/A, N=475, Completed, Sponsor: Massachusetts General Hospital
Initiation date: Dec 2015 --> Aug 2015 | Recruiting --> Terminated | Trial primary completion date: Oct 2020 --> Dec 2015; Due to low enrollment, registration closed in agreement with the Regulatory Agency Active, not recruiting --> Completed
- | dimethyl fumarate / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Adherence: Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients. (clinicaltrials.gov) - Nov 24, 2015
P4, N=84, Terminated, Sponsor: Biogen
Active, not recruiting --> Completed N=450 --> 84 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Feb 2016; Sponsor Decision
- || vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (clinicaltrials.gov) - Nov 22, 2015
P2, N=168, Enrolling by invitation, Sponsor: Genzyme, a Sanofi Company
N=450 --> 84 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Feb 2016; Sponsor Decision Trial primary completion date: Jan 2020 --> Apr 2016
- Trial completion, Enrollment change: Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis (clinicaltrials.gov) - Nov 19, 2015
P=N/A, N=60, Completed, Sponsor: Sunnybrook Health Sciences Centre
Trial primary completion date: Jan 2020 --> Apr 2016 Enrolling by invitation --> Completed | N=50 --> 60
- Trial primary completion date: The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=1000, Recruiting, Sponsor: Duke University
Enrolling by invitation --> Completed | N=50 --> 60 Trial primary completion date: Aug 2015 --> Aug 2016
- Trial primary completion date, Surgery: BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis) (clinicaltrials.gov) - Nov 17, 2015
P3, N=679, Recruiting, Sponsor: S. Anna Hospital
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Feb 2014 --> Dec 2015
- Trial completion: The CARRA Registry (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=9587, Completed, Sponsor: Duke University
Trial primary completion date: Feb 2014 --> Dec 2015 Enrolling by invitation --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
Trial termination: ASCEND: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 16, 2015
P3, N=889, Terminated, Sponsor: Biogen
Enrolling by invitation --> Completed Active, not recruiting --> Terminated; The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.
- | Vitaros (alprostadil + novel excipient) / Seelos Therap
Enrollment change: Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Nov 14, 2015
P2, N=35, Active, not recruiting, Sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Active, not recruiting --> Terminated; The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints. N=45 --> 35
- ||| dalfampridine / Generic mfg.
Trial completion: Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 12, 2015
P=N/A, N=52, Completed, Sponsor: Mount Sinai Rehabilitation Hospital
N=45 --> 35 Active, not recruiting --> Completed
- Trial primary completion date: Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=108, Recruiting, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Sep 2016
- Trial primary completion date: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Nov 5, 2015
P1, N=20, Active, not recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- ZB-168 / Zura Bio
Trial termination, Trial primary completion date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 5, 2015
P1, N=60, Terminated, Sponsor: Pfizer
Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2016; This study terminated on April 8, 2015 due to a corporate decision and not related to the safety or efficacy of the protocol.
- Trial primary completion date: BCI: EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Nov 1, 2015
P=N/A, N=150, Recruiting, Sponsor: Drexel University College of Medicine
Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2016; This study terminated on April 8, 2015 due to a corporate decision and not related to the safety or efficacy of the protocol. Trial primary completion date: Dec 2014 --> Dec 2020
- || opicinumab (BIIB033) / Biogen, Avonex (recombinant IFN-β-1a) / Biogen
Trial primary completion date: SYNERGY: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (clinicaltrials.gov) - Oct 28, 2015
P2, N=419, Active, not recruiting, Sponsor: Biogen
Trial primary completion date: Dec 2014 --> Dec 2020 Trial primary completion date: Mar 2016 --> Dec 2015
- || Betaseron (IFN-β-1b) / Bayer
Enrollment closed: Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (clinicaltrials.gov) - Oct 28, 2015
P=N/A, N=629, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Mar 2016 --> Dec 2015 Recruiting --> Active, not recruiting
- ||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion, Enrollment change: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (clinicaltrials.gov) - Oct 28, 2015
P3, N=1077, Completed, Sponsor: Biogen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=1500 --> 1077
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: China Betaferon Adherence, Coping and Nurse Support Study (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=110, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | N=1500 --> 1077 Active, not recruiting --> Completed
- || Trial primary completion date, Patient reported outcomes: PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=240, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Dec 2016
- Trial primary completion date: Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=100, Recruiting, Sponsor: Claudio Gobbi
Trial primary completion date: Jan 2016 --> Dec 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- Trial primary completion date: AERCONN: Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=60, Recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Sep 2015 --> Apr 2016
- methylphenidate tablet / Generic mfg.
Trial primary completion date: Methylphenidate to Improve Balance and Walking in MS (clinicaltrials.gov) - Oct 23, 2015
P2/3, N=24, Recruiting, Sponsor: Oregon Health and Science University
Trial primary completion date: Sep 2015 --> Apr 2016 Trial primary completion date: Jul 2015 --> Jan 2016
- Enrollment open, Phase classification: Mindfulness-based Stress Reduction for Multiple Sclerosis (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=60, Recruiting, Sponsor: National College of Natural Medicine
Trial primary completion date: Jul 2015 --> Jan 2016 Not yet recruiting --> Recruiting | Phase classification: P1/2 --> PN/A
- dimethyl fumarate / Generic mfg.
Enrollment change, Trial termination: IIT9: Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation (clinicaltrials.gov) - Oct 23, 2015
P4, N=31, Terminated, Sponsor: Rocky Mountain MS Research Group, LLC
Not yet recruiting --> Recruiting | Phase classification: P1/2 --> PN/A N=100 --> 31 | Recruiting --> Terminated; Study did not meet required enrollment numbers
- Trial primary completion date, Immunomodulating: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=18, Active, not recruiting, Sponsor: University of Wisconsin, Madison
N=100 --> 31 | Recruiting --> Terminated; Study did not meet required enrollment numbers Trial primary completion date: Mar 2015 --> Mar 2017
- prednisone / Generic mfg.
Trial termination: Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2015
P4, N=40, Terminated, Sponsor: Claudio Gobbi
Trial primary completion date: Mar 2015 --> Mar 2017 Recruiting --> Terminated; Difficulties to recruit patients